TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06346652

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy
Description: Routine physical therapy involving muscle strengthening exercises, range of motion exercises and stretching exercises up to patient's tolerance. Other exercises were pelvic bridging, rolling, sitting and standing exercises, walking practice and balancing in parallel bars, wobble board exercises. Each session was of 60 minutes 5 times weekly for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical Therapy+ PNF and Core Stregthening
Description: Routine physical therapy for 20 minutes and additionally PNF technique (rhythmic initiation, and then agonistic reversals were performed in lower extremity in D1 flexion pattern and D1 extension pattern up to patient's tolerance and core strengthening for 20 minutes 5 times weekly for 6 weeks.
Study: NCT05924607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard clamshells method
Description: The patient is asked to lie in a side-lying position with the weak limb up, both hips flexed at 45°, the knees flexed at 90°, and neither the feet nor back not in contact with the wall. Keeping both their heels and the first metatarsal head together, the patient separated their knees and rotated the weak limb upward. The patients is instructed not to tip it backward and to hold the pelvis in a neutral position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted VMO strengthening
Description: Targeted VMO strengthening The patient is asked to lie in a supine lying position with arm next to the body. After that asked the patient to perform SLR exercise in an external hip rotation with the simultaneous contraction of the ankle dorsiflexors. Common treatment will be given to each patient includes hot pack for 10 minutes and knee isometric contraction exercises and SLR( 3-5 sets of 10 repetitions
Study: NCT05046743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colonic gas load
Description: Colonic infusion of gas via an anal cannula

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham load
Description: Sham infusion of gas via an anal cannula
Study: NCT05931978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CKD dashboard
Description: Online dashboard that visualizes patients' individual PROM- and clinical data related to their kidney disease.
Study: NCT06451211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200 mg will be administered systemically on day 1 of each cycle in all participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 150 mg will be administered systemically on day 1 of each cycle in all participants
Study: NCT05333393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DİABOT (mobile application robot )
Description: Thanks to the trainings given through the mobile application robot developed for pediatric diabetes management, it is aimed to have an effect on the quality of life, diabetes self-management and physiological parameter levels of children with Type 1 diabetes, and to easily obtain the information they need even when they cannot come to the outpatient clinic. In addition, thanks to the application robot, he will be able to create his own exercise program and determine his diet.
Study: NCT06493708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trauma focused psychotherapy: EMDR
Description: 14 sessions of psychotherapy with EMDR will be carried out with patients. One session per week, lasting 90 minutes. The first two sessions will be used for the description of the EMDR method and for stabilization, then there will be treatment sessions.
Study: NCT05814887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReLink
Description: Medical device
Study: NCT06451211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 40 mg will be administered orally on day 1-14 of each cycle in all participants
Study: NCT06404606

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Black cumin and turmeric with Quantum Acoustic Waves (QAW)
Description: Black cumin and turmeric are known to be helpful in reduction of inflammation of human body so it will be used in combination with Quantum Acoustic Waves (QAW) to determine effects on initial degenerative changes in osteoarthritis.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Black cumin and turmeric with Quantum Acoustic Waves (QAW)
Description: Black cumin and turmeric are known to be helpful in reduction of inflammation of human body so it will be used in combination with Quantum Acoustic Waves (QAW) to determine effects on initial degenerative changes in osteoarthritis.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Black cumin and turmeric with Quantum Acoustic Waves (QAW)
Description: Black cumin and turmeric are known to be helpful in reduction of inflammation of human body so it will be used in combination with Quantum Acoustic Waves (QAW) to determine effects on initial degenerative changes in osteoarthritis.
Study: NCT06451211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 2500 mg will be administered orally on day 1-14 of each cycle in all participants
Study: NCT05543876

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suturing procedure
Description: Children presenting to the emergency department for suturing
Study: NCT05810792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histamine Dihydrochloride (HDC)
Description: HDC is administrated in combination with IL-2 as peri- and post-operative treatment in patients undergoing surgery. 0.5 mg HDC is administered twice daily by subcutaneous injections 1 to 3 minutes after each IL-2 injection during three 3 week cycles, with 3-week resting periods inbetween. The first treatment cycle is initated 2 weeks prior to surgery, with an additional 2-3 days rest period during the surgical procedure, before the third treatment week is initiated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2)
Description: IL-2 is administrated in combination with HDC during three 3 week cycles as peri- and post-operative treatment in patients undergoing surgery. IL-2 is administered twice daily as a subcutaneous injection 1 to 3 minutes prior to the administration of histamine dihydrochloride; each dose of IL-2 is 16,400 IU/kg (1µg/kg).
Study: NCT05785260

Intervention type: BEHAVIORAL
Intervention: ACT MINDFULNESS
Description: Mindfulness (MCBT) practices were offered to patients with the aim of fostering the elderly's pro-active role in health prevention by making them~aware of the relationship between thoughts, emotions and symptomatology of the disorder. The exercises will also be used as a motivational work tool within a protocol of Acceptance and Commitment Therapy (ACT), a new generation cognitive behavioral approach, in which commitment components are added to mindfulness, suitable for lifestyle modification.

Intervention type: BEHAVIORAL
Intervention: ACT MINDFULNESS
Description: Mindfulness (MCBT) practices were offered to patients with the aim of fostering the elderly's pro-active role in health prevention by making them~aware of the relationship between thoughts, emotions and symptomatology of the disorder. The exercises will also be used as a motivational work tool within a protocol of Acceptance and Commitment Therapy (ACT), a new generation cognitive behavioral approach, in which commitment components are added to mindfulness, suitable for lifestyle modification.
Study: NCT05304143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Immersive Reality Glasses
Description: The day of the examination, the patient will go to the MRI room and he will be fitted with virtual reality glasses compatible with the MRI equipment. The patient will visualize relaxing contents in open spaces with music and verbal instructions during all the procedure. The contents will be previously validated by the clinical psychologist of the center with experience in this regard.~During the test, the patient's heart rate will be monitored.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional nurse support
Description: Patients will be treated using the usual support technique to reduce anxiety in the Diagnostic Imaging service
Study: NCT05295823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Butterfly portable ultrasound device with bladder ultrasound images
Description: Point-of-care PVR measurement using existing ultrasound technology (3 consecutive measurements during the same encounter) the Butterfly portable ultrasound device with bladder ultrasound images

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Butterfly portable ultrasound device with bladder ultrasound images
Description: Point-of-care PVR measurement using existing ultrasound technology (3 consecutive measurements during the same encounter) the Butterfly portable ultrasound device with bladder ultrasound images

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Butterfly portable ultrasound device with abstract bladder images
Description: Point-of-care PVR measurement using the Butterfly portable ultrasound device with abstract bladder images

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Butterfly portable ultrasound device with abstract bladder images
Description: Point-of-care PVR measurement using the Butterfly portable ultrasound device with abstract bladder images
Study: NCT05944562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tulmimetostat
Description: Patients should take CPI-0209 at approximately the same time every morning in a fasted state (no food for 2 hours prior and 1 hour following CPI-0209 dosing). Each dose of CPI-0209 should be taken with a glass of water and consumed over as short a time as possible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tulmimetostat
Description: Patients should take CPI-0209 at approximately the same time every morning in a fasted state (no food for 2 hours prior and 1 hour following CPI-0209 dosing). Each dose of CPI-0209 should be taken with a glass of water and consumed over as short a time as possible.
Study: NCT05057806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: Empagliflozin 25MG will be administered orally once per day for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered orally once per day for 3 months
Study: NCT05585151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 MG/ML
Description: Evolocumab 140mg, subcutaneous injection, every 2 weeks, for 26 week, total 13 times

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensive statin treatment
Description: Intensive statin could choose either Atorvastatin 40mg/day or Rosuvastatin 20mg/day, for 26 weeks
Study: NCT06402760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TCM comprehensive treatment
Description: 1. Taodan Granules (TCM formulation for promoting blood circulation and removing blood stasis): The granules consist of the following herbal components: milkvetch, licorice, angelica, rhizoma chuanxiong, peach seed, Salvia miltiorrhiza, Curcuma zedoaria, Achyranthes bidentata, and sarsaparilla. Patients will take it orally in two divided doses after breakfast and dinner.~2. Fish Oil: Patients will take 1g of fish oil orally twice daily. Patients will be instructed to purchase fish oil under the guidance of the researchers.~3. Exercise Plan: Researchers will design an exercise plan for patients, who will be required to engage in at least 150 minutes of moderate-intensity aerobic exercise per week.~Patients will undergo a 16-week treatment period followed by a 24-week follow-up period. During the follow-up, patients will continue taking fish oil and adhering to the exercise regimen, while other treatment modalities will be unrestricted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Western medicine
Description: The treatment methods prescribed in the guidelines.
Study: NCT04736953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05814198

Intervention type: DIAGNOSTIC_TEST
Intervention: HALP score
Description: we will calculate the HALP score with the complete blood count and albumin values in FGR and SGA groups.

Intervention type: DIAGNOSTIC_TEST
Intervention: HALP score
Description: we will calculate the HALP score with the complete blood count and albumin values in FGR and SGA groups.
Study: NCT04890366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate
Description: Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
Study: NCT05517382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supportED
Description: suicide prevention videogame

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: non-health related videogame
Study: NCT05608109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol personalized normative feedback (APNF)
Description: Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's drinking compared to other same-university students will include: (a) drinking days per week, (b) average drinks per occasion, (c) drinks per week, and (d) drinking percentile rank.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol personalized normative feedback (APNF)
Description: Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's drinking compared to other same-university students will include: (a) drinking days per week, (b) average drinks per occasion, (c) drinks per week, and (d) drinking percentile rank.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social media personalized normative feedback (SMPNF)
Description: Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's alcohol related content posts on social media and drinking compared to other same-university students will include: (a) alcohol related posting days per week, (b) average alcohol related posting per week, (c) posting percentile rank, (d) drinking days per week, (e) average drinks per week, and (f) drinking percentile rank.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social media personalized normative feedback (SMPNF)
Description: Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's alcohol related content posts on social media and drinking compared to other same-university students will include: (a) alcohol related posting days per week, (b) average alcohol related posting per week, (c) posting percentile rank, (d) drinking days per week, (e) average drinks per week, and (f) drinking percentile rank.
Study: NCT05507255

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation training
Description: Relaxation training in the form of deep breathing exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation training
Description: Relaxation training in the form of deep breathing exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An aerobic exercise program
Description: An aerobic exercise program of a moderate intensity, based on the target heart rate (THR) that will be calculated in accordance with Karvonen's equation, using resting heart rate (HRrest), maximal heart rate (HRmax) and training fraction. THR = HRrest (bpm) + (HRmax (bpm) - HRrest (bpm)) × training fraction.The exercise session will have three phases, warming up, active phase and cooling down.
Study: NCT06447727

Intervention type: DRUG
Intervention: SIRT with Yttrium-90 Microspheres
Description: Selective Internal Radiation Therapy (SIRT) with Yttrium-90 \[90Y\] Microspheres Injection

Intervention type: DRUG
Intervention: FOLFIRI and Bevacizumab
Description: FOLFIRI and Bevacizumab
Study: NCT06213168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFNC
Description: Patients assigned to the control group will be continuously treated by HFNC. HFNC will be initiated within one hour following randomization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFNC
Description: Patients assigned to the control group will be continuously treated by HFNC. HFNC will be initiated within one hour following randomization
Study: NCT05857449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3480392
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3480392
Description: Intravenous infusion
Study: NCT05318612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Interstitial Thermal Therapy (LITT)
Description: LITT is a minimally invasive neurosurgical procedure in which a laser catheter is placed into the tumor and warms the tumor to such an extent that tumor tissue is destroyed. LITT is performed under MR-guidance.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: A sample of tissue from the tumor is obtained to confirm the diagnosis.
Study: NCT06352528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repotrectinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repotrectinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repotrectinib
Description: Specified dose on specified days
Study: NCT04862897

Intervention type: OTHER
Intervention: Patient-controlled admissions
Description: Patients are allowed to admit themselves to inpatient care when needed (standard procedure, four days of inpatient care at a time, up to three times a month)
Study: NCT05751889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serious Game
Description: Serious Game embedded with healthcare information regarding HCV and safe sexual practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Health Education
Description: Reading materials regarding HCV and safe sexual practice.
Study: NCT05993273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural
Description: The epidural catheter is placed while the patient is awake, before the induction of general anesthesia. The intervertebral spaces used for catheter insertion are alternatively T4-T5, T5-6 or T6-T7. After locating the epidural space through the technique of the loss of resistance, a catheter is introduced for about 5 cm and left in place for the administration of drugs into the epidural space. Once the correct functioning of the epidural catheter has been verified with a negative test for cerebrospinal fluid aspiration and a negative bolus test for the onset of signs and symptoms from intrathecal infusion, the catheter is used intraoperatively for administration of local anesthetics in refracted boluses (Lidocaine and Ropivacaine ) at anesthetic dosage and postoperatively for continuous infusion of Ropivacaine 0.15% at 5 mL/h.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP block
Description: Erector spinae plane (ESP) block is performed after induction of general anesthesia, with the patient in a lateral decubitus position. With the aid of the ultrasound guide with linear probe, the transverse process of T5 ipsilateral to the site of the operation is identified. With the in-plane technique, the lower fascia of the ESP muscle is hydrodissected through the administration of Ropivacaine 0.5% 3 mg/Kg lean body weight. Subsequently, a catheter is introduced and left in place for continuous postoperative infusion of Ropivacaine 0.2% at 12 mL/h.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoanalgesia
Description: Cryoanalgesia is performed after the induction of general anesthesia, single lung ventilation and after performing the first thoracoscopic surgical access. A cryoanesthesia device with a dedicated atraumatic angled-tip cryoprobe is inserted through the thoracoscopic access. The active tip of the probe is positioned in contact with the intercostal nerves from T3 to T8 and kept resting for 4 ½ minutes on each nerve at a temperature of -70°C, under direct thoracoscopic vision, generating an interruption of the sensory functions.
Study: NCT06239090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehacor-T
Description: During each session of bio/neurofeedback IG patients will view their recorded brain waves and physiological responses in a computer screen, while a professional will explain to them what they need to do to intervene and make corrective changes to their brain waves.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: SG patients will be given irrelevant information (recorded data of other patients) and thus, they cannot modulate their cortical activation and see only the scenarios
Study: NCT02823132

Intervention type: BIOLOGICAL
Intervention: blood sample

Intervention type: BIOLOGICAL
Intervention: blood sample
Study: NCT04718948

Intervention type: DEVICE
Intervention: Urinary Multimodal Fiber Optic Spectroscopy
Description: Approach based on a physical principle, mainly spectroscopy, which is rapid non-invasive and does not require the use of additional substances or contrast media in the diagnosis of urothelial neoplasms in urine samples.~It will be administered through a appositely designed device

Intervention type: DEVICE
Intervention: Urinary Multimodal Fiber Optic Spectroscopy
Description: Approach based on a physical principle, mainly spectroscopy, which is rapid non-invasive and does not require the use of additional substances or contrast media in the diagnosis of urothelial neoplasms in urine samples.~It will be administered through a appositely designed device

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Cytology
Description: An expert cytopathologist will analyze urine samples to detect urinary tract cancer cells. It is the current golden standard to detect urothelial cancer in urine

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Cytology
Description: An expert cytopathologist will analyze urine samples to detect urinary tract cancer cells. It is the current golden standard to detect urothelial cancer in urine

Intervention type: PROCEDURE
Intervention: Surgery
Description: It will provide a reliable information on the presence/absence of cancer in the urinary tract (from direct visualization to pathological analysis)

Intervention type: PROCEDURE
Intervention: Surgery
Description: It will provide a reliable information on the presence/absence of cancer in the urinary tract (from direct visualization to pathological analysis)
Study: NCT06213168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP and HFNC
Description: Patients assigned to the intervention group will receive high flow nasal oxygen plus CPAP sessions
Study: NCT04711408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SootheVR: AppliedVR, Los Angeles, California a head-mounted displa
Description: For the study group, virtual reality content will be administered to the participant for the duration of the examination through a head-mounted display, RelieVRTM. The VR content for the trial will be swimming with dolphins.
Study: NCT05249361

Intervention type: OTHER
Intervention: no intervention
Description: no intervention